| Autoimmune Bullous Skin Diseases | Lifetime | 37 | ES 1 | 99.42 |
| Psoriasis: Treatment and Pathogenesis | Lifetime | 34 | ES 1 | 99.56 |
| Dermatology and Skin Diseases | Lifetime | 71 | ES 1 | 99.55 |
| Pharmaceutical studies and practices | Lifetime | 66 | ES 1 | 99.10 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 433 | ES 5 | 98.85 |
| Asthma and respiratory diseases | Lifetime | 450 | ES 12 | 98.89 |
| Biosimilars and Bioanalytical Methods | Lifetime | 102 | ES 4 | 97.91 |
| Spondyloarthritis Studies and Treatments | Lifetime | 114 | ES 5 | 98.71 |
| Autoimmune and Inflammatory Disorders Research | Lifetime | 192 | ES 3 | 98.67 |
| Rheumatoid Arthritis Research and Therapies | Lifetime | 536 | ES 17 | 97.86 |
| Urticaria and Related Conditions | Lifetime | 326 | ES 12 | 97.19 |
| Cancer and Skin Lesions | Lifetime | 414 | ES 16 | 96.78 |
| Autoimmune and Inflammatory Disorders | Lifetime | 245 | ES 12 | 96.45 |
| Dermatological and COVID-19 studies | Lifetime | 118 | ES 9 | 93.21 |
| Vascular Malformations and Hemangiomas | Lifetime | 381 | ES 8 | 94.22 |
| Nail Diseases and Treatments | Lifetime | 702 | ES 18 | 95.11 |
| Tumors and Oncological Cases | Lifetime | 732 | ES 17 | 93.85 |
| Hidradenitis Suppurativa and Treatments | Lifetime | 103 | ES 5 | 94.21 |
| Therapeutic Uses of Natural Elements | Lifetime | 189 | ES 13 | 92.80 |
| Complementary and Alternative Medicine Studies | Lifetime | 579 | ES 2 | 93.01 |
| Skin Diseases and Diabetes | Lifetime | 261 | ES 8 | 92.55 |
| Drug-Induced Adverse Reactions | Lifetime | 660 | ES 40 | 92.83 |
| Cutaneous lymphoproliferative disorders research | Lifetime | 857 | ES 31 | 93.05 |
| Genetic and rare skin diseases. | Lifetime | 477 | ES 19 | 90.91 |
| Acne and Rosacea Treatments and Effects | Lifetime | 561 | ES 5 | 90.06 |
| Dermatological and Skeletal Disorders | Lifetime | 693 | ES 12 | 88.87 |
| Histiocytic Disorders and Treatments | Lifetime | 700 | ES 13 | 85.86 |
| Soft tissue tumors and treatment | Lifetime | 701 | ES 19 | 70.19 |
| Psoriasis: Treatment and Pathogenesis | 2021-2025 | 1 | ES 1 | 99.89 |
| Dermatology and Skin Diseases | 2021-2025 | 7 | ES 1 | 99.78 |
| Pharmaceutical studies and practices | 2021-2025 | 7 | ES 1 | 99.16 |
| Asthma and respiratory diseases | 2021-2025 | 31 | ES 2 | 99.55 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 66 | ES 2 | 98.96 |
| Autoimmune Bullous Skin Diseases | 2021-2025 | 34 | ES 1 | 98.52 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 45 | ES 1 | 94.41 |
| Urticaria and Related Conditions | 2021-2025 | 73 | ES 3 | 96.56 |
| Spondyloarthritis Studies and Treatments | 2021-2025 | 119 | ES 8 | 96.43 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 145 | ES 7 | 92.26 |
| Autoimmune and Inflammatory Disorders Research | 2021-2025 | 607 | ES 17 | 88.14 |
| Nail Diseases and Treatments | 2021-2025 | 309 | ES 11 | 85.67 |
| Allergic Rhinitis and Sensitization | 2021-2025 | 823 | ES 46 | 87.87 |
| Hidradenitis Suppurativa and Treatments | 2021-2025 | 146 | ES 9 | 84.69 |
| Complementary and Alternative Medicine Studies | 2021-2025 | 386 | ES 3 | 78.88 |
| Vascular Malformations and Hemangiomas | 2021-2025 | 406 | ES 13 | 71.43 |
| Chemotherapy-related skin toxicity | 2021-2025 | 289 | ES 12 | 62.35 |
| Intramuscular injections and effects | 2021-2025 | 211 | ES 3 | 54.17 |
| Dermatological diseases and infestations | 2021-2025 | 951 | ES 43 | 34.56 |